Anthropic partners with six life sciences firms as Claude speeds drug development 89%
mark_k · x · 2026-10-28
Anthropic is partnering with six life sciences companies to apply Claude to drug discovery, clinical research, and regulatory workflows, with notable early results:
- Enveda cut review times by 89% while flagging additional issues
- Divergence Labs generated 35,000 antibody designs targeting food allergies, with promising lab results
- Generate Biomedicines built a more efficient component for CAR-T cancer therapy
Anthropic also acquired Mithril Medicine, a one-person biotech that advanced a muscular dystrophy treatment from concept to successful mouse studies in under 18 months; human trials could begin by late 2028.
More from Companies & People
- Computer scientist on being interviewed by an "AI Reporter": honesty made it fine — fortnow · 2026-10-28
- Google brings Gemini Robotics ER 2 embodied reasoning model to Google Cloud — ZoubinGhahrama1 · 2026-10-28
- Anthropic's $850K multi-agent role tops list of 25 highest-paying open jobs — lennysan · 2026-10-28
- X Launches Photo Resharing With Auto Creator Credit and Revenue Split for Both Parties — Polymarket · 2026-10-28
- Anthropic Enters Drug Discovery a Day After IPO Filing, Sparking Competing-With-Customers Debate — IgorCarron · 2026-10-28
- MIT opens registration for Zero Robotics 2027: code NASA's Astrobee robots on the ISS — RosalindPicard · 2026-10-28